

Benefit of Screening Colonoscopy to Average-Risk Medicare Beneficiaries

Gerald C Hsu*

Department of Cancer, Aristide Le Dantec Hospital, Dakar, Senegal

Abstract

Although the in vitro analysis of cultured cell lines is associated with artifacts related to effects attributed to a non-physiological environment and long-term passage in culture, it was shown that cancer cell lines retain most of the genomic features of the primary tumour. This has not yet been shown for proteomic features of cancer cell lines.

Introduction

Acknowledgement

Conflict of Interest

References

1. Fidalgo JAP, Roda D, Roselló S (2009) Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system. *Clin Transl Oncol EU* 11:787-798.
2. Folkman J (2003) Angiogenesis inhibitors: a new class of drugs. *Cancer Biol Ther US* 2:126-132.
3. Sano M (2018) A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. *J Cardiol EU* 71: 471-476.
4. Sacchi S, Rosini E, Pollegioni L, Gianluca M (2013) D-amino acid oxidase inhibitors as a novel class of drugs for schizophrenia therapy. *Curr Pharm Des UAE* 19:2499-2511.
5. Li B, Chau JFL, Wang X (2011) Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy. *J Cell Biochem US* 112:1229-1242.
6. Kyttaris VC (2012) Kinase inhibitors: a new class of antirheumatic drugs. *Drug Des Devel Ther UK* 6: 245-250.
7. Weber MA (2001) Vasopeptidase inhibitors. *Lancet EU* 358: 1525-1532.
8. Kittleson MM, Hare JM (2005) Xanthine oxidase inhibitors: an emerging class of drugs for heart failure. *Heart UK* 91:707-709.
9. Doan NB (2017) Acid ceramidase and its inhibitors: A de novo drug target and a new class of drugs for killing glioblastoma cancer stem cells with high efficiency. *Oncotarget USA* 8:112662-112674.
10. Stroissnigg FH, Ling YY, Zhao J (2017) Identification of HSP90 inhibitors as a novel class of senolytics. *Nat Commun EU* 8: 1-14.

*Corresponding author: Gerald C Hsu, Department of Cancer, Aristide Le Dantec Hospital, Dakar, Senegal, E-mail: chsu@hotmail.com

Received: 01-Jul-2023, Manuscript No. ACP-23-107933; **Editor assigned:** 05-Jul-2023, PreQC No. ACP-23-107933 (PQ); **Reviewed:** 19-Jul-2023, QC No. ACP-23-107933; **Revised:** 24-Jul-2023, Manuscript No. ACP-23-107933 (R); **Published:** 31-Jul-2023; DOI: 10.4172/2472-0429.1000174

Citation: Hsu GC (2023) Benefit of Screening Colonoscopy to Average-Risk Medicare Beneficiaries. *Adv Cancer Prev* 7: 174.

Copyright: © 2023 Hsu GC. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.